Trial Profile
An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs IMM 101 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Immodulon Therapeutics
- 08 Jul 2019 Status changed from active, no longer recruiting to completed.
- 08 Oct 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2023.
- 08 Oct 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2022.